In line with our findings that TSCL are present in the tumor, expand in response to combination therapy before tumor regression, and can give rise to several TEFF cell subsets, we observed an increase in the percentage of IFNγ+ CD8 T cells in combination-treated tumors compared to control and anti-TGFβ treatment by flow cytometry (Fig. 6a). The gene discussed is CD8A; the disease is neoplasm.